Arena (ARNA), Orexigen (OREX) on Watch as Major PBM Adds Qsymia to Formularies List (VVUS)
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS, Inc. (NASDAQ: VVUS) peers Arena Pharmaceutials (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX) are ticking higher following reports that major Pharmacy Benefit Manager (PBM) Express Scripts (Nasdaq: ESRX) added VIVUS' obesity pill Qsymia to its its national pharmacy formularies.
For more color, click here.
Both Arena and Orexigen are flat early.
For more color, click here.
Both Arena and Orexigen are flat early.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- FibroBiologics ships third CYWC628 batch to Australia for DFU trial
- Verrica completes enrollment in YCANTH wart trial, data due Q1 2027
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
